Incidence and mortality of breast cancer. What did we achieve?;Mammakarzinom: Inzidenz und mortalität in den letzten 25 jahren. Was haben wir erreicht?

Gynakologe

Volumn 35, Issue 7, 2002, Pages 680-688

  Thomssen, C ^a,b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Adjuvant therapy; Breast cancer; Incidence; Mortality; Screening

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DISEASE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS; SCREENING TEST;

EID: 0036933976     PISSN: 00175994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00129-002-1223-3     Document Type: Article

References (33)

1. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland. 3. erweiterte, aktualisierte Ausgabe, Saarbrücken, 2002
2. Homepage des Robert-Koch-Institutes: http://www.rki.de/KREBS
3. Peto R, Boreham J, Clarke M et al. (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355: 1822
4. Epidemiologisches Krebsregister Saarland (1998) Morbidität und Mortalität an Bösartigen Neubildungen im Saarland 1994 und 1995 - Jahresbericht des Saarländischen Krebsregisters. Sonderheft des Statistischen Landesamtes Saarland Nr. 191, Epidemiologisches Krebsregister Saarland, http://www.krebsregister.saarland.de
5. D. Hölzel, A. Klamert, M.Schmidt. Krebs (1996) Häufigkeiten, Befunde und Behandlungsergebnisse. Perspektiven für die Krebsregisterdiskussion und für eine quantitative klinischepidemiologische Onkologie aus dem Tumor-register München. Zuckschwerdt, München (Tumorregister München, http://www.med.uni-muenchen.de/trm)
6. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (eds) (2001) SEER Cancer Statistics Review, 1973-1998, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/Publications/CSR1973_1998/
7. EBCTCG (2000) Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 355: 1757-1770
8. EBCTCG (1996) Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 348: 1189-1196
9. EBCTCG (1998a) Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352: 930-942
10. EBCTCG (1998b) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451-1467
11. Anderson RN (1998) United States abridged life tables. National vital statistics reports, vol 47, no. 13. National Center for Health Statistics, Hyattsville, Maryland
12. Paci E, Giorgi D, Bianchi S,Vezzosi V, Zappa M, Crocetti E, Rosselli del Turco M. (2002) Assessment of the early impact of the population based breast cancer screening programme in Florence (Italy) using mortality and surrogate measures. Eur J Cancer 38: 568-573
13. Glass AG, Hoover RN (1990) Rising incidence of breast cancer: relationship to stage and receptor status. J Natl Cancer Inst 80: 693
14. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL,Cronin WM (1995) Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333: 1456-1461
15. Veronesi U, Salvadori B, Luini A et al. (1995) Breast conservation is a safe method in patients with small cancer of the breast. Longterm results of three randomised trials on 1,973 patients. Eur J Cancer 31: 1574-1579
16. Levine MN, Bramwell VH, Pritchard KI et al. (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate,and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2568
17. Greenspan EM (1986) Commentary on September 1985 NIH Consensus Development Conference on Adjuvant Chemotherapy for Breast Cancer. Cancer Invest 4: 471-475
18. Zujewski J, Liu ET (1998) The 1998 St. Gallen's Consensus Conference: an assessment. J Natl Cancer Inst 4: 1587-1589
19. Cady B (2002) Breast cancer: An introduction to the problem. In: Marchant DJ (ed) Breast disease: Diagnosis and contemporary management. Obstet Gynecol Clin North Am 29: 117-122
20. American Cancer Society (2001) Cancer prevention and early detection facts and figures 2001. American Cancer Society Atlanta, pp 23-24
21. Feig SA (2002) Current status of screening mammography. In: Marchant DJ (ed) Breast disease: Diagnosis and contemporary management. Obstet Gynecol Clin North Am 29: 123-136
22. Tabar L, Chen HH, Duffy SW, Krusemo UB (1999) Primary and adjuvant therapy, prognostic factors and survival in 1053 breast cancers diagnosed in a trial of mammography screening. Jpn J Clin Oncol 29: 608-616
23. Tabar L, Vitak B, Chen HH et al. (2000) The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am 38: 625-651
24. Tabar L, Vitak B, Cen H-HT et al. (2001) Beyond randomized controlled trials: Organized mammographic screening substantially reduces breast cancer mortality. Cancer 91: 1724-1731
25. Shapiro S (1997) Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan. J Natl Cancer Inst Monogr 22: 27-30
26. Shapiro S, Venet W, Strax P, Venet L, Roeser R (1985) Selection, follow-up, and analysis in the Health Insurance Plan Study: a randomized trial with breast cancer screening. Natl Cancer Inst Monogr 67: 65-74
27. Alexander FE, Anderson TJ, Brown HK et al. (1999) 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet 353: 1903-1908
28. Gelmon KA, Olivotto I (2002) The mammography screening debate: time to move on. Lancet 359: 904-905
29. Feig SA (1995) Estimation of currently attainable benefit from mammography screening of women aged 40-49 years. Cancer 75: 2412-2419
30. Bjurstam N, Bjorneld L, Duffy SW et al. (1997) The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer 80: 2091-2099
31. Feig SA (1997) Increased benefit from shorter screening mammography intervals for women ages 40-49. Cancer 80: 2035-2039
32. Michaelson JS, Halpern E, Kopans B (1999) Breast cancer computer simulation method for estimation of optimal intervals for screening. Radiology 12: 551-560
33. Nyström L, Rutqvist LE, Wall S et al. (1993) Breast cancer screening with mammography: overview of Swedish randomised studies. Lancet 341: 973-978